| An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non muscle-invasive bladder cancer: Interim results |
29 |
| A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer |
18 |
| Robotic versus open partial nephrectomy for highly complex renal masses: Comparison of perioperative, functional, and oncological outcomes |
17 |
| Intratumor heterogeneity in prostate cancer |
16 |
| Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis |
15 |
| Depression and prostate cancer: A focused review for the clinician |
13 |
| Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy |
12 |
| Frailty as a predictor of complications after radical cystectomy: A prospective study of various preoperative assessments |
12 |
| Comparative effectiveness of robot-assisted vs. open radical cystectomy |
12 |
| Psychological and functional effect of different primary treatments for prostate cancer: A comparative prospective analysis |
12 |
| Neoadjuvant therapy for localized and locally advanced renal cell carcinoma |
12 |
| Decreasing suicide risk among patients with prostate cancer: Implications for depression, erectile dysfunction, and suicidal ideation screening |
11 |
| Mental health implications in bladder cancer patients: A review |
10 |
| Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore |
10 |
| A urinary microRNA (miR) signature for diagnosis of bladder cancer |
10 |
| Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab |
10 |
| Sarcomatoid renal cell carcinoma: Biology and treatment advances |
10 |
| Predictive factors for local recurrence after glansectomy and neoglans reconstruction for penile squamous cell carcinoma |
10 |
| Monopolar vs. bipolar transurethral resection for non muscle invasive bladder carcinoma: A post-hoc analysis from a randomized controlled trial |
10 |
| Prospective implementation of a nonopioid protocol for patients undergoing robot-assisted radical cystectomy with extracorporeal urinary diversion |
9 |
| Metabolic changes in bladder cancer |
9 |
| Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis |
9 |
| Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance-A systematic review |
9 |
| Impact of hospital case volume on testicular cancer outcomes and practice patterns |
9 |
| Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting |
9 |
| Partial nephrectomy versus radical nephrectomy for large (>= 7 cm) renal tumors: A systematic review and meta-analysis |
9 |
| Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study |
9 |
| The impact of statins in combination with androgen deprivation therapy in patients with advanced prostate cancer: A large observational study |
8 |
| Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry |
8 |
| Combination of androgen receptor inhibitor and cisplatin, an effective treatment strategy for urothelial carcinoma of the bladder |
8 |
| C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma - A data from multi-institutional study in Japan |
8 |
| Robot Assisted Radical Cystectomy vs Open Radical Cystectomy: Over 10 years of the Mayo Clinic Experience |
8 |
| Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder |
8 |
| Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma |
8 |
| Molecular basis of the effect of MMP-9 on the prostate bone metastasis: A review |
8 |
| Predicting morbidity after robotic partial nephrectomy: The effect of tumor, environment, and patient-related factors |
8 |
| Secondary data sources for health services research in urologic oncology |
8 |
| Recent developments in the treatment of advanced bladder cancer |
7 |
| Measurement of Urinary Level of a Specific Competing endogenous RNA network (FOS and RCAN mRNA/ miR-324-5p, miR-4738-3p, /lncRNA miR-497-HG) Enables Diagnosis of Bladder Cancer |
7 |
| A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review |
7 |
| Survival outcomes of organ sparing surgery, partial penectomy, and total penectomy in pathological T1/T2 penile cancer: Report from the National Cancer Data Base |
7 |
| Assessment of volume preservation performed before or after partial nephrectomy accurately predicts postoperative renal function: Results from a prospective multicenter study |
7 |
| Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature |
7 |
| Improved surgical outcomes following radical cystectomy at high-volume centers influence overall survival |
7 |
| High expression of long noncoding RNA NORAD indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer |
7 |
| Furan and p-xylene as candidate biomarkers for prostate cancer |
7 |
| A delay >= 8 weeks to neoadjuvant chemotherapy before radical cystectomy increases the risk of upstaging |
7 |
| An update of research evidence on nutrition and prostate cancer |
7 |
| MicroRNA-93 promotes bladder cancer proliferation and invasion by targeting PEDF |
6 |
| Diagnosis and management of the growing teratoma syndrome: A single-center experience and review of the literature |
6 |
